How to read a peptide research paper
- Identify the parts of a research paper and what each can — and cannot — tell you
- Recognize the main study designs and how they rank as evidence
- Spot red flags in methods and reporting
- Understand why one striking study is rarely the last word
Research papers follow a standard structure, and each section answers a different question. Learning that structure is the single highest-return skill for reading peptide research.
Anatomy of a paper
Abstract — a summary written after the fact. Useful for deciding whether to keep reading; dangerous for drawing conclusions. Never cite a paper you've only read the abstract of.
Introduction — background and why the authors think the question matters. Skim it.
Methods — what was actually done: who or what was studied, the design, the doses, the duration, and how outcomes were measured. Read this first and read it closely. Methods tell you whether results can apply to humans and whether the numbers mean what they seem to mean.
Results — the findings themselves, usually with statistics. Compare effect sizes and their uncertainty (confidence intervals), not just whether a result was "significant."
Discussion — the authors' interpretation. Valuable, but it is opinion backed by data. The limitations subsection is often the most honest paragraph in the paper.
Study designs, from strongest to weakest signals
Randomized controlled trials (RCTs) randomly assign human participants to groups, which is the best tool we have for isolating a compound's own effect from placebo effects, regression to the mean, and selection bias.
Other human research — cohort studies, open-label trials, case series — involves real humans but cannot fully separate the compound from other factors.
Animal research shows biological effects in a species that isn't ours. Doses are often far higher than anything used in humans, and many promising animal findings never translate.
Laboratory (in vitro) research demonstrates mechanisms in cells or tissues. It is where mechanisms get established — and where whole-body claims do not.
These are the same labels our study library and evidence explorer use, so you can see at a glance what kind of research stands behind any record on this site.
Red flags worth noticing
- Vested interests: check the funding and conflict-of-interest disclosures.
- Tiny samples or very short durations paired with sweeping conclusions.
- Outcome switching — the discussion emphasizes endpoints the study wasn't designed to test.
- A single study treated as settled science. One paper is a data point. Replication and meta-analyses are how fields converge on answers.
Where to keep going
Open any record in the study library and read its methods summary against the lesson above — then use the paper translator to check your reading of the original abstract. When you're comfortable with designs, the evidence explorer shows you what tier of research exists for each compound.
Key takeaways.
- Read the methods section first — it tells you who was studied and whether results apply to humans.
- Evidence tiers rank designs: randomized human trials, other human research, animal research, laboratory research.
- One study is a data point, not a conclusion — look for replication.
- The limitations paragraph is often the most honest part of a paper.
Check yourself.
4 questions. Answers are checked right here in your browser — retake as many times as you like.
1. Which section should you read first when evaluating a study?
2. Why can a striking animal result fail to translate to humans?
3. A single study reporting p < 0.05 means:
4. Open-label trials rank below randomized controlled trials because: